{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:35:55Z","timestamp":1782995755123,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.mehy.2015.06.024","type":"journal-article","created":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T21:31:49Z","timestamp":1436045509000},"page":"433-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is it the time to rethink clinical decision-making strategies? From a single clinical outcome evaluation to a Clinical Multi-criteria Decision Assessment (CMDA)"],"prefix":"10.1016","volume":"85","author":[{"given":"Alberto","family":"Migliore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Integlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Bizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomaso","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2015.06.024_b0005","doi-asserted-by":"crossref","unstructured":"Kenneth F Schulz, David A. Grimes Generation of allocation sequences in randomised trials: chance, not choice THE LANCET February 9, 2002;359:515\u201319.","DOI":"10.1016\/S0140-6736(02)07683-3"},{"issue":"2","key":"10.1016\/j.mehy.2015.06.024_b0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amepre.2007.04.007","article-title":"Limitations of the randomized controlled trial in evaluating population-based health interventions","volume":"33","author":"Sanson-Fisher","year":"2007","journal-title":"Am J Prev Med"},{"issue":"9453","key":"10.1016\/j.mehy.2015.06.024_b0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2015.06.024_b0020","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1001\/jama.289.19.2575","article-title":"Clinical trials\u2014multiple treatments, multiple end points, and multiple lessons","volume":"289","author":"Lauer","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.mehy.2015.06.024_b0025","series-title":"Introduction to Mixed Treatment Comparisons","author":"Ades","year":"2007"},{"key":"10.1016\/j.mehy.2015.06.024_b0030","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.mehy.2015.06.024_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis","volume":"24","author":"Ades","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.mehy.2015.06.024_b0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0272989X07309642","article-title":"Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights","volume":"28","author":"Mortimer","year":"2007","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.mehy.2015.06.024_b0045","first-page":"47","article-title":"Is it time to take a harder look at the QALY","volume":"5","author":"Brower","year":"2008","journal-title":"Biotechnol Healthc"},{"issue":"2","key":"10.1016\/j.mehy.2015.06.024_b0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ieam.137","article-title":"Scenario and multiple criteria decision analysis for energy and environmental security of military and industrial installations","volume":"7","author":"Karvetski","year":"2011","journal-title":"Integr Environ Assess Manage"},{"issue":"9","key":"10.1016\/j.mehy.2015.06.024_b0055","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1021\/es1031294","article-title":"Multiple-criteria decision analysis reveals high stakeholder preference to remove pharmaceuticals from hospital wastewater","volume":"45","author":"Lienert","year":"2011","journal-title":"Environ Sci Technol"},{"issue":"1","key":"10.1016\/j.mehy.2015.06.024_b0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00267-005-0111-8","article-title":"A combined MOIP-MCDA approach to building and screening atmospheric pollution control strategies in urban regions","volume":"38","author":"Mavrotas","year":"2006","journal-title":"Environ Manage"},{"issue":"6","key":"10.1016\/j.mehy.2015.06.024_b0065","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1081\/ESE-120004517","article-title":"Using multiple criteria decision analysis for supporting decisions of solid waste management","volume":"37","author":"Cheng","year":"2002","journal-title":"J Environ Sci Health A Tox Hazard Subst Environ Eng"},{"issue":"8","key":"10.1016\/j.mehy.2015.06.024_b0070","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jval.2012.06.015","article-title":"Multiple criteria decision analysis for health technology assessment","volume":"15","author":"Thokala","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.mehy.2015.06.024_b0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1108\/14777261211239007","article-title":"Social values and health priority setting in England: \u201cvalues\u201d based decision making","volume":"26","author":"Littlejohns","year":"2012","journal-title":"J Health Organ Manage"},{"key":"10.1016\/j.mehy.2015.06.024_b0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10198-013-0517-9","article-title":"Erik Buskens A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions","volume":"15","author":"Postmus","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.mehy.2015.06.024_b0085","series-title":"Multiple Criteria Decision Analysis: State of the Art Surveys Series","year":"2005"},{"key":"10.1016\/j.mehy.2015.06.024_b0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1478-7547-4-14","article-title":"Louis Niessen Priority setting of health interventions: the need for multi-criteria decision analysis","volume":"4","author":"Baltussen","year":"2006","journal-title":"Cost Effect Res Alloc"},{"key":"10.1016\/j.mehy.2015.06.024_b0095","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11657-014-0182-3","article-title":"Estimating prevalence of osteoporosis: examples from industrialized countries","volume":"9","author":"Wade","year":"2014","journal-title":"Arch Osteoporos"},{"issue":"5","key":"10.1016\/j.mehy.2015.06.024_b0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00223-014-9910-3","article-title":"Epidemiological burden of postmenopausal osteoporosis in Italy from 2010 to 2020: estimations from a disease model","volume":"95","author":"Piscitelli","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"10.1016\/j.mehy.2015.06.024_b0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.mehy.2015.06.024_b0110","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1359\/jbmr.2002.17.4.716","article-title":"Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study","volume":"17","author":"THE EUROPEAN PROSPECTIVE OSTEOPOROSIS STUDY (EPOS) GROUP","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.mehy.2015.06.024_b0115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/jwh.2013.4611","article-title":"Osteoporosis prevention, screening, and treatment a review","volume":"23","author":"Kling","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.mehy.2015.06.024_b0120","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2015.06.024_b0125","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausalosteoporosis: a randomized controlled trial.Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2015.06.024_b0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.mehy.2015.06.024_b0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral ibandronate study group. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"Mcclung","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.mehy.2015.06.024_b0140","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Horizon pivotal fracture trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.mehy.2015.06.024_b0145","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2015.06.024_b0150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptiveagents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2015.06.024_b0155","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.mehy.2015.06.024_b0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","article-title":"Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study","volume":"18","author":"Silverman","year":"2007","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.mehy.2015.06.024_b0165","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1185\/03007990903035281","article-title":"Prevention of vertebral fractures in osteoporosis: mixed comparision of bisphosphonates therapies","volume":"25","author":"Jansen","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mehy.2015.06.024_b0170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis","volume":"40","author":"Jansen","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mehy.2015.06.024_b0175","first-page":"658","article-title":"Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis","volume":"17","author":"Migliore","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.mehy.2015.06.024_b0180","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00223-009-9329-4","article-title":"Potential clinical and economic impact of nonadherence with osteoporosis medications","volume":"86","author":"Shiligsmann","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1016\/j.mehy.2015.06.024_b0185","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s10067-006-0240-3","article-title":"The burden of musculoskeletal disease\u2013a global perspective","volume":"25","author":"Brooks","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.mehy.2015.06.024_b0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mehy.2015.06.024_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2009.127225","article-title":"Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","author":"Gaujoux-Viala","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.mehy.2015.06.024_b0200","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.mehy.2015.06.024_b0205","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780380602","article-title":"ACR preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mehy.2015.06.024_b0210","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mehy.2015.06.024_b0215","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.mehy.2015.06.024_b0220","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","volume":"181","author":"Singh","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.mehy.2015.06.024_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mehy.2015.06.024_b0230","first-page":"429","article-title":"Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis analysis of American College of Rheumatology criteria scores 20, 50, and 70","volume":"6","author":"Orme","year":"2012","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.mehy.2015.06.024_b0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-12-102","article-title":"Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs \u2013 a systematic review and network meta-analysis","volume":"12","author":"Jansen","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.mehy.2015.06.024_b0240","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"1987"},{"key":"10.1016\/j.mehy.2015.06.024_b0245","series-title":"Multiple criteria decision analysis for Health Technology Assessment","author":"Thokala","year":"2012"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715002431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715002431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T04:27:20Z","timestamp":1537504040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987715002431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0306987715002431"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2015.06.024","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is it the time to rethink clinical decision-making strategies? From a single clinical outcome evaluation to a Clinical Multi-criteria Decision Assessment (CMDA)","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2015.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}